-
Signature
-
/s/ Richard Giroux
-
Issuer symbol
-
MGTX
-
Transactions as of
-
17 Jan 2026
-
Net transactions value
-
-$1,216,257
-
Form type
-
4
-
Filing time
-
21 Jan 2026, 21:13:39 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Giroux Richard |
CFO & COO |
655 THIRD AVENUE, SUITE 1115, NEW YORK |
/s/ Richard Giroux |
21 Jan 2026 |
0001742734 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
MGTX |
Ordinary Shares |
Options Exercise |
|
+310,000 |
+36% |
|
1,163,172 |
17 Jan 2026 |
Direct |
F1, F2 |
| transaction |
MGTX |
Ordinary Shares |
Tax liability |
$1,216,257 |
-163,916 |
-14% |
$7.42 |
999,256 |
17 Jan 2026 |
Direct |
F3 |
| holding |
MGTX |
Ordinary Shares |
|
|
|
|
|
5,152 |
17 Jan 2026 |
By Spouse |
|
| holding |
MGTX |
Ordinary Shares |
|
|
|
|
|
85,000 |
17 Jan 2026 |
By Aigle Healthcare Partners III LLC |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
MGTX |
Restricted Share Units |
Options Exercise |
$0 |
-310,000 |
-50% |
$0.000000 |
310,000 |
17 Jan 2026 |
Ordinary Shares |
310,000 |
|
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: